Akebia Therapeutics, Inc. (AKBA) NASDAQ
0.94
-0.0836(-8.20%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.94
-0.0836(-8.20%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.01 |
| Day High | 1.02 |
| Day Low | 0.91 |
| 52-Week High | 4.08 |
| 52-Week Low | 0.88 |
| Volume | 7.21M |
| Average Volume | 3.56M |
| Market Cap | 251.2M |
| PE | -11.7 |
| EPS | -0.08 |
| Moving Average 50 Days | 1.29 |
| Moving Average 200 Days | 1.84 |
| Change | -0.08 |
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Execut
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
GlobeNewswire Inc.
Feb 19, 2026 1:00 PM GMT
Akebia to Host Conference Call on February 26 at 8:00 a.m. ESTCAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team